Takeda Pharmaceutical Company Limited TAK
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -0.07% | 0.91% | 3.07% | -4.63% | -1.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.07% | 0.91% | 3.07% | -4.63% | -1.13% |
| Cost of Revenue | -4.16% | 17.94% | -4.78% | -2.85% | 7.28% |
| Gross Profit | 2.11% | -8.44% | 7.57% | -5.53% | -5.10% |
| SG&A Expenses | 1.51% | -4.15% | 3.42% | -4.75% | 2.27% |
| Depreciation & Amortization | -26.03% | -26.02% | 0.42% | -4.61% | 0.68% |
| Other Operating Expenses | 101.41% | 26.71% | -52.60% | 136.67% | -51.62% |
| Total Operating Expenses | -1.46% | 0.90% | -7.12% | 1.86% | -0.54% |
| Operating Income | 7.64% | 0.97% | 952.52% | -29.52% | -4.29% |
| Income Before Tax | -2.07% | -311.84% | 401.64% | -76.21% | 19.00% |
| Income Tax Expenses | 70.16% | -1,902.31% | 1,059.27% | 47.50% | -31.15% |
| Earnings from Continuing Operations | -17.39% | -247.03% | 330.67% | -112.84% | 40.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -51.06% | -5.64% | -102.22% | -18.96% | 23.81% |
| Net Income | -17.40% | -246.90% | 331.11% | -112.92% | 40.77% |
| EBIT | 7.64% | 0.97% | 952.52% | -29.52% | -4.29% |
| EBITDA | -5.97% | -13.19% | 58.99% | -17.86% | -1.14% |
| EPS Basic | -18.21% | -247.22% | 332.93% | -112.96% | 41.16% |
| Normalized Basic EPS | 7.63% | -38.78% | 342.27% | -33.80% | -9.13% |
| EPS Diluted | -18.24% | -247.22% | 325.71% | -113.18% | 40.82% |
| Normalized Diluted EPS | 7.56% | -38.78% | 338.30% | -32.68% | -9.32% |
| Average Basic Shares Outstanding | 0.97% | -0.10% | -0.39% | -0.34% | -0.27% |
| Average Diluted Shares Outstanding | 1.04% | -0.10% | 1.28% | -1.99% | -0.06% |
| Dividend Per Share | -- | -0.90% | -- | 2.85% | -- |
| Payout Ratio | 0.13% | 0.75% | -0.76% | -8.45% | -0.19% |